Insulet Corporation (PODD)
- Previous Close
310.67 - Open
313.46 - Bid 288.23 x 200
- Ask 335.24 x 200
- Day's Range
305.95 - 318.86 - 52 Week Range
160.19 - 318.86 - Volume
1,364,033 - Avg. Volume
896,185 - Market Cap (intraday)
22.286B - Beta (5Y Monthly) 1.27
- PE Ratio (TTM)
56.96 - EPS (TTM)
5.56 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
321.14
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
www.insulet.comRecent News: PODD
View More
Related Videos: PODD
Performance Overview: PODD
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PODD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PODD
View MoreValuation Measures
Market Cap
21.86B
Enterprise Value
22.28B
Trailing P/E
55.98
Forward P/E
74.63
PEG Ratio (5yr expected)
7.88
Price/Sales (ttm)
10.45
Price/Book (mrq)
16.43
Enterprise Value/Revenue
10.13
Enterprise Value/EBITDA
53.25
Financial Highlights
Profitability and Income Statement
Profit Margin
18.29%
Return on Assets (ttm)
6.94%
Return on Equity (ttm)
37.92%
Revenue (ttm)
2.2B
Net Income Avi to Common (ttm)
402.2M
Diluted EPS (ttm)
5.56
Balance Sheet and Cash Flow
Total Cash (mrq)
1.28B
Total Debt/Equity (mrq)
127.41%
Levered Free Cash Flow (ttm)
84.25M
Research Analysis: PODD
View MoreResearch Reports: PODD
View MoreInsulet Earnings: Exceptional Start to 2025 Coincides With Major Management Change
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
RatingPrice TargetInsulet Earnings: Exceptional Start to 2025 Coincides With Major Management Change
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
RatingPrice TargetRaising target price to $285.00
INSULET CORP has an Investment Rating of BUY; a target price of $285.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice TargetLowering target price to $277.00
INSULET CORP has an Investment Rating of BUY; a target price of $277.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Medium.
RatingPrice Target